Expression and Cellular Localization of Follicle-Stimulating Hormone Receptor in Normal Human Prostate, Benign Prostatic Hyperplasia and Prostate Cancer

Journal of Urology

Volumn 175, Issue 6, 2006, Pages 2072-2077

  Mariani, Stefania ^a   Salvatori, Luisa ^a,b   Basciani, Sabrina ^a   Arizzi, Mario ^a   Franco, Giorgio ^a   Petrangeli, Elisa ^a,b   Spera, Giovanni ^a   Gnessi, Lucio ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b CNR   (Italy)

Author keywords

adenocarcinoma; FSH; prostate; prostatic hyperplasia; prostatic neoplasms; receptors

Indexed keywords

CYCLIC AMP; FOLLITROPIN; FOLLITROPIN RECEPTOR; MESSENGER RNA;

ARTICLE; CANCER CELL CULTURE; CELL STIMULATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; EPITHELIUM; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STROMA CELL; AGED; BIOSYNTHESIS; CHEMISTRY; COMPARATIVE STUDY; METABOLISM; MIDDLE AGED; PROSTATE TUMOR; TUMOR CELL LINE;

AGED; CELL LINE, TUMOR; HUMANS; MALE; MIDDLE AGED; PROSTATE; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; RECEPTORS, FSH;

EID: 33746233569     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(06)00273-4     Document Type: Article

References (22)

1. Merrill R.M., and Morris M.K. Prevalence-corrected prostate cancer incidence rates and trends. Am J Epidemiol 155 (2002) 148
2. Aus G., Robinson D., Rosell J., Sandblom G., Varenhorst E., and South-East Region Prostate Cancer Group. Survival in prostate carcinoma: outcomes from a prospective, population-based cohort of 8,887 men with up to 15 years of follow-up: results from three countries in the population-based National Prostate Cancer Registry of Sweden. Cancer 103 (2005) 943
3. Ruijter E., Van De Kaa C., Miller G., Ruiter D., Debruyne F., and Schalken J. Molecular genetics and epidemiology of prostate carcinoma. Endocr Rev 20 (1999) 22
4. Kambhampati S., Ray G., Sengupta K., Reddy V.P., Banerjee S.K., and Van Veldhuizen P.J. Growth factors involved in prostate carcinogenesis. Front Biasci 10 (2005) 1355
5. Di Sant'Agnese P.A. Neuroendocrine differentiation in prostatic carcinoma. an update. Prostate 8 (1998) 74
6. Garde S.V., Sheth A.R., Shah M.G., and Kulkarni S.A. Prostate: an extrapituitary source of follicle-stimulating hormone (FSH): occurrence, localization, and de novo biosynthesis and its hormonal modulation in primates and rodents. Prostate 18 (1991) 271
7. Shah M.G., and Sheth A.R. Similarities in the modulation of pituitary and prostatic FSH by inhibin and related peptides. Prostate 18 (1991) 1
8. Hurkadli K.S., Sheth A.R., Garde S.V., Doctor V.M., and Sheth N.A. Immunocytochemical localization of follicle stimulating hormone (FSH) in normal, benign and malignant human prostates. Br J Cancer 61 (1990) 225
9. Dirnhofer S., Berger C., Hermann M., Steiner G., Madersbacher S., and Berger P. Coexpression of gonadotropic hormones and their corresponding FSH- and LH/CG-receptors in the human prostate. Prostate 35 (1998) 212
10. Ben-Josef E., Yang S.Y., Ji T.H., Bidart J.M., Garde S.V., Chopra D.P., et al. Hormone-refractory prostate cancer cells express functional follicle-stimulating hormone receptor (FSHR). J Urol 161 (1999) 970
11. Porter A.T., and Ben-Josef E. Humoral mechanisms in prostate cancer. a role for FSH. Urol Oncol 6 (2001) 131
12. Marcelli M., Ittmann M., Mariani S., Sutherland R., Nigam R., and Murthy L. Androgen receptor mutations in prostate cancer. Cancer Res 60 (2000) 944
13. Basciani S., Mariani S., Arizzi M., Brama M., Ricci A., Betsholtz C., et al. Expression of platelet-derived growth factor (PDGF) in the epididymis and analysis of the epididymal development in PDGF-A, PDGF-B, and PDGF receptor beta deficient mice. Biol Reprod 70 (2004) 168
14. Dierich A., Sairam M.R., Monaco L., Fimia G.M., Gansmuller A., LeMeur M., et al. Impairing follicle-stimulating hormone (FSH) signaling in vivo. targeted disruption of the FSH receptor leads to aberrant gametogenesis and hormonal imbalance. Proc Natl Acad Sci USA 95 (1998) 13612
15. Garde S.V., Sheth A.R., Joseph R., Panchal C.J., Chinoy R.F., and Sheth N.A. Occurrence and de novo biosynthesis of follicle stimulating hormone (FSH) in benign and malignant conditions of human breast. Cancer Lett 75 (1993) 1
16. Syed V., Ulinski G., Mok S.C., Yiu G.K., and Ho S.M. Expression of gonadotropin receptor and growth responses to key reproductive hormones in normal and malignant human ovarian surface epithelial cells. Cancer Res 61 (2001) 6768
17. Zheng W., Lu J.J., Luo F., Zheng Y., Feng Y., Felix J.C., et al. Ovarian epithelial tumor growth promotion by follicle-stimulating hormone and inhibition of the effect by luteinizing hormone. Gynecol Oncol 76 (2000) 80
18. Choi J.H., Choi K.C., Auersperg N., and Leung P.C. Overexpression of follicle-stimulating hormone receptor activates oncogenic pathways in preneoplastic ovarian surface epithelial cells. J Clin Endocrinol Metab 89 (2004) 5508
19. Morley J.E., Kaiser F.E., Perry III H.M., Patrick P., Morley P.M., Stauber P.M., et al. Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men. Metabolism 46 (1997) 410
20. d'Ancona F.C.H., and Debruyne F.M.J. Endocrine approaches in the therapy of prostate carcinoma. Hum Reprod Update 11 (2005) 309
21. Garnick M.B., Campion M., and Abarelix Depot study group. Abarelix Depot, a GnRH antagonist, v LHRH superagonists in prostate cancer. differential effects on follicle-stimulating hormone. Mol Urol 4 (2000) 275
22. Beer T.M., Garzotto M., Eilers K.M., Lemmon D., and Wersinger E.M. Targeting FSH in androgen-independent prostate cancer. abarelix for prostate cancer progressing after orchiectomy. Urology 63 (2004) 342